Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
企業コードLLY
会社名Eli Lilly and Co
上場日Jul 09, 1970
最高経営責任者「CEO」Ricks (David A)
従業員数47000
証券種類Ordinary Share
決算期末Jul 09
本社所在地Lilly Corporate Ctr
都市INDIANAPOLIS
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号46285
電話番号13172762000
ウェブサイトhttps://www.lilly.com/
企業コードLLY
上場日Jul 09, 1970
最高経営責任者「CEO」Ricks (David A)